RAPP Stock Analysis: Buy, Sell, or Hold?
RAPP - Rapport Therapeutics, Inc. Common Stock
$41.56
0.97 (2.39%)
▲
5d:
+4.63%
30d:
+18.03%
90d:
+19.94%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When RAPP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RAPP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RAPP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RAPP is currently trading at $41.56, which is considered extended relative to its 30-day fair value range of $36.85 to $40.93.
Technical Outlook: Technically, RAPP is in a strong uptrend. Immediate support is located at $38.48, while resistance sits at $43.76.
Market Sentiment: RAPP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $56.64 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RAPP is in a strong uptrend. Immediate support is located at $38.48, while resistance sits at $43.76.
Market Sentiment: RAPP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $56.64 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$36.85 -
$40.93
Company Quality Score
65/100
(BUY)
Options IV Signal
16th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.5% below Wall St target ($56.64)
Trading Range Analysis
30-Day Trading Range
$36.85 -
$40.93
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.38
(8.1%)
Support & Resistance Levels
Support Level
$38.48
Resistance Level
$43.76
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.23
Wall Street Target
$56.64
(+39.5%)
Share & Embed Analysis
Last updated: July 14, 2026 12:59 PM ET
Data refreshes hourly during market hours. Next update: 1:59 PM
Data refreshes hourly during market hours. Next update: 1:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RAPP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Rock Ventures V L.P. Thi…
SELL
426005 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
20225 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
10200 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |